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The dramatic rise of oseltamivir resistance in the H1N1 serotype in the 2007/2008 season 
and the fixing of H274Y in the 2008/2009 season has raised concerns regarding 
individuals at risk for seasonal influenza, as well as development of similar resistance in 
the H5N1 serotype.  Previously, oseltamivir resistance produced changes in H1N1 and 
H3N2 at multiple positions in treated patients.  In contrast, the recently reported 
resistance involved patients who had not recently taken oseltamivir.  Moreover, the 
resistance was limited to the H1N1 which had acquired H274Y.  Using phylogenetic 
analysis I show that the fixing of H274Y was due to hitch hiking on a genetic background 
that acquired key changes from another circulating sub-clade.  H274Y jumped from clade 
2C (Hong Kong/2562/2006-like) to clade 1 (New Caledonia/20/1999-like) to clade 2B 
(Brisbane/59/2007-like) which included multiple introductions. Sub-clades that had 
acquired key changes on the neuramindase and hemagglutinin genes expanded and fixed 
of H274Y on H1N1.  These changes led to the spread of adamantane resistance on clade 
2C outside of Asia, followed by the spread of oseltamivir resistance in 2007/2008 and the 
fixing of H274Y in 2008/2009.  The hemagglutinin change, A193T, was a key 
component and the coincident polymorphism, S193F, was linked to the fixing of 
adamantane resistance in H3N2.  The aggregation of key polymorphisms onto different 
genetic backgrounds supports a mechanism of homologous recombination between co-
circulating influenza sub-clades, and provides a rationale for the prediction of vaccine 
targets and emergence of antiviral resistance. 
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The recent reports1,2 of high levels of osletamivir (neuraminidase inhibitor) resistance in 
seasonal influenza have caused concern because the resistance was in patients who had 
not recently taken osletamivir3, and the genetic change, H274Y, was the same change that 
confers resistance to oseltamivir in the potential pandemic influenza sub-type, H5N14.  
Moreover, the resistance was specific for H1N1 and position H274Y, supporting the 
notion that the high levels was not linked to oseltamivir usage. 
 
Prior studies of oseltamivir resistance in Japan5 were linked to sub-optimal dosing and 
resistance was found in both current influenza A subtypes, H1N1 and H3N2, and 
included, but was not limited to H274Y.  Prior studies also supported a fitness penalty6,7 
for the acquisition of H274Y, which predicted that the change would be limited to 
patients receiving oseltamivir. 
 
However, the appearance of H274Y in hosts not receiving oseltamivir was reported in 
wild birds infected with H5N1 in Astrakhan, which was followed by patients in China 
infected with H1N1 in 20068.  Earlier H1N1 isolates had been closely related to the 
H1N1 vaccine target, isolated in New Caledonia in 1999 and designated clade 1 
(prototype New Caledonia/20/1999).  Subsequent sub-clades were designated clade 2 and 
divided into three sub-clades, 2A (prototype A/Solomon Island/3/2006), 2B (prototype 
A/Brisbane/59/2007) and 2C (prototype A/Hong Kong/2562/2006) – see the 
neuraminidase (NA) phylogenetic tree in Figure 1.  The patients from China 
demonstrated that the absence of a fitness penalty in the H5N1 wild birds extended to 
H1N1 seasonal flu, but the H274Y frequency remained low as seen in the multiple 
introductions in Figure 1A. 
 
In the 2006/2007 season H274Y appeared on another H1N1 genetic background, clade 1 
(Figure 1A). The clade 1 result was similar to clade 2C.  Patients not taking oseltamivir 
were infected with oseltamivir resistant H1N1.  However, the levels remained low even 
though the distribution on the phylogenetic tree supported multiple independent 
introductions, indicating that H1N1 with H274Y had not gained a significant selection 
advantage. 
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 In the 2007/2008 season, H274Y appeared on yet another H1N1 genetic background, 
Clade 2B.  The first reported isolates in the United States were in Hawaii (Figure 1A red 
box), and this subclade was subsequently identified in Scotland and England, followed by 
France and Japan in 2008.  However, the frequency of this sub-clade remained low.  
Subsequently, a much larger sub-clade emerged (Figure 1A (Clade 2B* in powder blue 
box). 
 
Figure 2B details some of the NA changes associated with this emergence. Two tandem 
polymorphisms, D344N and D354G (encoded by G1030A and A1061G, respectively)  
defined Clade 2B* that was widespread by the end of 2007, and in early 2008 led to 
frequencies greater than 50% of H274Y in  H1N1, which were reported in Norway 9.  
These two polymorphisms were in clade 1 H1N1 isolates from 2001/2002. Levels of 
H1N1 declined after the 2003/2004 season, and began to emerge in Asia in 2005/2006. 
Clade 2C emerged in 2006/2007 and had acquired D344N and D354G, as well as a 
synonymous polymorphism, G1041A.  Clade 1 emerged worldwide in the 2006/2007 
season, but did not have the three polymorphisms.  Clade 2B expanded in 2007/2008 and 
the dominate sub-clade, including Brisbane/59 had D344N.  However, Clade 2B* 
emerged with the same three polymorphisms which appeared in the prior season in Clade 
2C.  Moreover, flanking regions created a 80 BP stretch of identity between Clade 2B 
and Clade 2C, supporting acquisition by homologous recombination. 
 
Phylogenetic analysis of HA is presented in Figure 2.  Figure 2A supports the data in the 
NA phylogram, showing multiple independent introductions in clade 2C, clade 1, and 
early clade 2B, followed by the emergence of Clade 2B*.  Clade 2C had three receptor 
binding domain changes, R192M, A193T, and T197K (Figure 2B).  A sub-clade of Clade 
2B*, Clade 2B** emerged in multiple locations in the United States as well as England. 
It had acquired A193T 
 
The high levels reported in several countries in Europe were surpassed in the 2008 
influenza season in the southern hemisphere.  Resistance levels rose to 100% in South 
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Africa10, suggesting additional changes were creating strong selection pressure.  HA 
sequences from South Africa identified a dominant sub-clade with five polymorphisms 
clustered around receptor binding domain position 190 (H3 numbering).  Four of these 
nucleotide changes produce three non-synonymous polymorphisms, N187D, G189N, and 
A193T (see Figure 2B).  All three changes were present in other recent H1N1 isolates. 
A193T was present in Clade 2B* in the 2007-2008 season.  N187D was in an H1N1 
clade 2C isolate from Hong Kong.  G189N was encoded by two adjacent nucleotide 
changes that were in clade 2B isolates from Kenya. 
 
The presence of A193T in a sub-set of isolates in Clade 2B* and the dominant sub-clade 
in South Africa, was extended to isolates from the current season.  The fixing of H274Y 
in clade 2B in South Africa was extended to North America and Europe this season.  All 
clade 2B isolates reported to date in the United States and Canada have H274Y.  As seen 
in figure 2, all isolates from the United States this season are on the same branch and all 
isolates have A193T, suggesting this change drove the fixing of H274Y in H1N1 clade 
2B.  The isolates have additional changes at position 190 (D190N), as well as the 
adjacent position (G189V), which may be linked to further selection.  A recent report 
from Japan identified sequences which matched isolates from the United States.  One 
group had G189V, A193T, and H186R.  Another series had G189N and A193T, while 
another series had G189A and A193T, supporting the importance of A193T. 
 
The fixing and spread of H274Y in clade 2B, is similar to the emergence of adamantine 
resistance associated with S31N in MP2 in H1N1 clade 2C.  Although S31N was 
becoming fixed in a sub-clade in China in the 2006/2007 season, its spread to multiple 
countries, including the United States was linked to a 2C sub-clade that had acquired a 
number of changes near position 190 (R192M, A193T, and T197K).  This sub-clade 
represented approximately 10% of H1N1 isolates in the United States, and all had S31N.  
Moreover, as seen in Figure 2, the same sub-clade was found in Air Force personal or 
dependents in South Korea, Japan, Marian Islands, Hawaii, and Georgia supporting a 
significant expansion of this sub-clade. 
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The presence of HA A193T in clade 2B isolates that had fixed NA H274Y as well as 
clade 2C isolates that had fixed M2 S31N suggests that the spread of the resistance was 
due to genetic hitch hiking of the resistance markers with HA receptor binding domain 
changes.  This mechanism is supported further by the fixing of M2 S31N in H3N2, which 
was associated with two HA receptor binding domain changes, D225N and S193F.  The 
association of position 193 with the fixing and spread of antiviral resistance strongly 
supports genetic hitch hiking as the mechanism of the fixing of these three examples of 
antiviral resistance.  Moreover, recent Clade 2C isolates from Hong Kong have both 
H274Y on NA and S31N on M2. 
 
The acquisition of changes in the H1N1 is most easily explained by homologous 
recombination.  The changes in the receptor binding domain were appended onto a clade 
2B genetic background that had A193T.  One of the changes, N187D, is rare but is found 
in a 2008 clade 2C isolate in Hong Kong.  The other change is also rare and requires 
tandem nucleotide changes.  The same two changes are found in 2008 H1N1 isolates 
from Kenya.  Acquisition of these changes by independent copy errors is unlikely since 
the donor sequences are in Africa in 2008, and the changes were among a limited number 
of changes on the South African sub-clade. 
 
Acquisition by homologous recombination is also supported by the dominant changes in 
NA and HA.  The tandem changes of D344N and D354G11 are present on three different 
genetic backgrounds, H1N1 in circulation between 2001 and 2003, clade 2C emergence 
with S31N in 2007, and clade 2B emergence with H274Y in 2007.  Similarly the 
emergence of these two recent sub-clades was associated with the acquisition of A193T 
on HA, which was also in H1N2 isolates that emerged in 2003. 
 
The exchanges of genetic information between clade 2B and clade 2C are facilitated by 
co-circulation. In addition to the presence of N187D on clade 2B in South Africa and 
clade 2C in Hong Kong, one of the Hong Kong isolates is a reassortant, with a clade 2C 
HA and a clade 2B NA.  Moreover, this isolate, and others collected over the summer in 
Hong Kong have a clade 2C HA and M2 which has H274Y in NA (both clade 2B and 
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clade C) as well as S31N on M2, signaling additional exchanges of polymorphisms 
leading to the emergence of H1N1 which is resistant to oseltamivir and the adamantanes. 
 
Moreover, H274Y was associated with independent introductions onto multiple 
independent H1N1 backgrounds (clade 2C, clade 1, and clade 2B) which are also most 
easily explained by homologous recombination.  The introduction onto multiple 
backgrounds followed by widespread fixing is similar to a synonymous change on H1N1 
clade 2.2 NA, G743A12.  This polymorphism was on a geographically and genetically 
restricted sub-clade in 2006.  However, in early 2007 it appeared on multiple clade 2.2 
genetic backgrounds in Russia, Egypt, Kuwait, Ghana, and Nigeria.  The change was then 
fixed on clade 2,2,3 which evolved from its introduction in Kuwait in early 2007 and 
became fixed in Europe in the 2007/2008 season. 
 
The movement of single nucleotide polymorphisms via recombination between closely 
related sequences is not unexpected. Earlier analysis of swine influenza identified 
multiple examples of recombination involving long stretches of identity.  However, 
multiple recombination events led to shorter regions from a given parental sequence13-15.  
Shorter regions were identified in an analysis of human influenza16.  Similarly, the 
exchanges have also been seen for deletions.  A three BP deletion appended onto H5N1 
clade 2.2 in Egypt was identical to the deletion appended onto a clade 7 background in 
China17.  Moreover, recombination between closely related sequences, such as H1N1 
sub-clades as described in this report, or between sub-clades of H5N1 described above, 
produces exchanges of single nucleotide polymorphisms. 
 
The fixing of antiviral resistance follows a general mechanism for rapid viral evolution. 
Recombination places a given polymorphism onto multiple genetic backgrounds.  Most 
of the initial introductions failed to become dominant.  This was seen in the United States 
in the first clade 2B isolates which were in Hawaii.  These isolates formed a branch with 
other isolates from Hawaii and California, but this sub-clade did not spread beyond the 
initial two isolates.  The pattern was repeated for a Florida isolate that formed a separate 
branch, but the H274Y on this background also did not spread.  Similar results were seen 
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for an isolate from France, which spread to a minor sub-clade in South Africa.  The sub-
clade in Norway also did not spread beyond adjacent countries (Finland and Denmark).  
However, the acquisition of H274Y by isolates with A193T in 2007/2008 was followed 
by fixing in Europe and North America in the following season, supporting the 
emergence and spread by genetic hitch hiking.   
 
This mechanism has significant theoretical and practical considerations.  The acquisition 
of polymorphisms that have a circulated previously allows for predictions based on the 
present and past frequency of the polymorphisms as well as likely interactions between 
various genomes.  In the fixing of H274Y, the polymorphism appeared on multiple H1N1 
sub-clades before it was fixed throughout the northern hemisphere.  The fixing was 
associated with the acquisition of a number of additional polymorphisms on NA and HA.  
The acquisition of A193T was preceded by its association with the fixing of S31N in M2 
of H1N1 clade 2C18, and a change at the same position on H3, S193F, was associated 
with the fixing of S31N on H3N219,20.  Thus, the appearance of A193T at the end of 2007 
was a signal that it would play a role in the spread of H274Y in the following season. 
 
The role of A193T in the emergence of H274Y may extend beyond an immunological 
escape mechanism.  The position has been reported to be associated with a change in 
tissue tropism, which affects affinity and is expressed in a species specific manner21.  
Moreover, the dominant H1N1 reported to date for this season includes an adjacent 
change, H196R, which also has been linked to an affinity changes in H5N1 on a clade 1 
background in Vietnam, as well as a clade 2.2 background in Iraq.  In both instances the 
change was Q196R22.  The H5N1 studies also associated position 186 in changes in 
affinity for receptors on target cells, and position 190 has been associated with species 
specific changes23. 
 
Therefore, changes in or near the receptor binding domain in HA are candidates for 
vaccine targets.  A193T was circulating in late 2007 and early 2008 in the United States 
and England, signaling its fixing in the following season in the northern hemisphere.  
Although the selection of Brisbane/59 for the vaccine target was considered a “match” 
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for the H1N1 in the 2008/2009 season, it did not contain A193T.  Moreover, A193T has 
not been included in any of the H1N1 vaccine targets, raising the possibility that its 
absence in recent vaccines played a role in its emergence in clade 2C in Asia, followed 
by clade 2B worldwide.  Similarly, one of the NA changes associated with the emergence 
of H274Y, D354G, as well as H274Y itself have not been present in recent H1N1 vaccine 
targets. 
 
In addition to the prediction of vaccine targets, the pattern of polymorphism acquisition 
can be used to predict the fixing of drug resistance, such as H274Y for oseltamivir, or 
S31N for adamantanes in H1N1 or H3N2.  The emergence of the resistance has led to a 
more robust influenza database, most notably for HA, NA, and MP gene segments.  
However, an expanded database with sequences from more locations in Asia and Africa 
should create more accurate predictions of emerging polymorphisms for use in predicting 
vaccine targets and fixing of antiviral resistance. 
 
Figures 
 
Figure 1.  NA Phylogram of H1N1 Isolates. 
 
NA phylogram of positions 601-1095. Trees generated using neighbor joining and 100 
bootstrap repetitions.  Isolates with H274Y marked with (*).  Isolates with known S31N 
on M2 marked with (@). A. Expansion of clade 1, 2B, 2C. B.  Non-synonymous 
polymorphisms in blue.  Synonymous polymorphism in red. D344N encoded by 
G1030A.  D354G encoded by A1061G. 
 
Figure 2.  HA Phylogram of H1N1 and H1N2 Isolates 
 
HA phylogram of positions 69-632.  Trees generated using neighbor joining and 100 
bootstrap repetitions.  Isolates with H274Y marked with (*).  Isolates with known S31N 
on M2 marked with (@). A. Expansion of clade 1, 2B, 2C. B.  N187S encoded by 
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A599G. G189N encoded by G604A and G605A. R192M encoded by G614A. A193T 
encoded by G616A.  T197K encoded by C629A. 
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Figure 1A.  NA Phylogram of H1N1 Isolates 
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Figure 1B.  NA Phylogram of H1N1 Isolates 
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Figure 2A.  HA Phylogram of H1N1 and H1N2 Isolates 
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Figure 2B.  HA Phylogram of H1N1 and H1N2 Isolates 
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